Acreage Living, December 2001, Vol.7, no.12

Monthly newsletter for people in Iowa that live on Acreages, produced by Iowa State University Copperative Extension.

Acreage Living, December 2001, Vol.7, no.12

Monthly newsletter for people in Iowa that live on Acreages, produced by Iowa State University Copperative Extension.

Acreage Living, July 2002, Vol.8, no.7

Monthly newsletter for people in Iowa that live on Acreages, produced by Iowa State University Copperative Extension.

A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors.

BACKGROUND: Humanized KS-interleukin-2 (huKS-IL2), an immunocytokine with specificity for epithelial cell adhesion molecule (EpCAM), has demonstrated favorable tolerability and immunologic activity as a single agent. METHODS: Phase 1b study in patients with EpCAM-positive advanced solid tumors to determine the maximum tolerated dose (MTD) and safety profile of huKS-IL2 in combination with low-dose cyclophosphamide. Treatment consisted of cyclophosphamide (300 mg/m2 on day 1), and escalating doses of huKS-IL2 (0.5-4.0 mg/m2 IV continuous infusion over 4 hours) on days 2, 3, and 4 of each 21-day cycle. Safety, pharmacokinetic profile, immunogenicity, anti-tumor and biologic activity were evaluated. RESULTS: Twenty-seven patients were treated for up to 6 cycles; 26 were evaluable for response. The MTD of huKS-IL2 in combination with 300 mg/m2 cyclophosphamide was 3.0 mg/m2. At higher doses, myelosuppression was dose-limiting. Transient lymphopenia was the most common grade 3/4 adverse event (AE). Other significant AEs included hypotension, hypophosphatemia, and increase in serum creatinine. All patients recovered from these AEs. The huKS-IL2 exposure was dose-dependent, but not dose-proportional, accumulation was negligible, and elimination half-life and systemic clearance were independent of dose and time. Most patients had a transient immune response to huKS-IL2. Immunologic activity was observed at all doses. Ten patients (38%) had stable disease as best response, lasting for ≥ 4 cycles in 3 patients. CONCLUSION: The combination of huKS-IL2 with low-dose cyclophosphamide was well tolerated. Although no objective responses were observed, the combination showed evidence of immunologic activity and 3 patients showed stable disease for ≥ 4 cycles. TRIAL REGISTRATION: http://NCT00132522.

Recueil des lettres missives de Henri IV. T. 7 / publié par M. Berger de Xivrey,...

Collection : Collection de documents inédits sur l'histoire de France

EPI Update, October 7 2005

Weekly newsletter for Center For Acute Disease Epidemiology of Iowa Department of Public Health.

EPI Update, October 7 2005

Weekly newsletter for Center For Acute Disease Epidemiology of Iowa Department of Public Health.

Dispensable role of myeloid differentiation primary response gene 88 (MyD88) and MyD88-dependent toll-like receptors (TLRs) in a murine model of osteoarthritis.

OBJECTIVES: The aim of our study was to evaluate the role of cell-membrane expressed TLRs and the signaling molecule MyD88 in a murine model of OA induced by knee menisectomy (surgical partial removal of the medial meniscus [MNX]). METHODS: OA was induced in 8-10weeks old C57Bl/6 wild-type (WT) female (n=7) mice and in knockout (KO) TLR-1 (n=7), -2 (n=8), -4 (n=9) -6 (n=5), MyD88 (n=8) mice by medial menisectomy, using the sham-operated contralateral knee as a control. Cartilage destruction and synovial inflammation were evaluated by knee joint histology using the OARSI scoring method. Apoptotic chondrocytes and cartilage metabolism (collagen II synthesis and MMP-mediated aggrecan degradation) were analyzed using immunohistochemistry. RESULTS: Operated knees exhibited OA features at 8weeks post-surgery compared to sham-operated ones. In menisectomized TLR-1, -2, -4, and -6 deficient mice, cartilage lesions, synovial inflammation and cartilage metabolism were similar to that in operated WT mice. Accordingly, using the same approach, we found no significant protection in MyD88-deficient mice in terms of OA progression as compared to WT littermates. CONCLUSIONS: Deficiency of TLRs or their signalling molecule MyD88 did not impact on the severity of experimental OA. Our results demonstrate that MyD88-dependent TLRs are not involved in this murine OA model. Moreover, the dispensable role of MyD88, which is also an adaptor for IL-1 receptor signaling, suggests that IL-1 is not a key mediator in the development of OA. This latter hypothesis is strengthened by the lack of efficiency of IL-1β antagonist in the treatment of OA.

Report of Recommendations to the State University of Iowa on the Review of Selected General and Application Controls over the University's Human Resources Information System, June 7, 2005-July 29, 2005

Other Audit Reports - Regent Institutions

Iowa Community Empowerment Newsletter, April 2006, Vol.7, no.2

Monthly newsletter for the Iowa Department of Public Health

KH-7

El trabajo que presentamos a continuación analiza la situación de la empresa KH Lloreda en el mercado de productos desengrasantes. Concretamente hemos profundizado en la estrategia de márketing utilizada en la empresa a la hora de lanzar su producto KH-7.Decidimos elegir la empresa KH Lloreda y más concretamente el producto KH-7 porque nos llamó la atención que un producto destinado al uso diario de la limpieza del hogar hubiera tenido tanto éxito. ¿Cuál es la característica innovadora que hace que la gente prefiera este producto? Otro factor que también ha sido decisivo a la hora de elegir la empresa es la evolución de la compañía. Una empresa catalana de origen familiar ha logrado hacerse un hueco en el mercado y, en determinados sectores, ha logrado superar a grandes multinacionales. por esto hemos aprovechado esta ocasión para estudiar las estrategias que ha utilizado la empresa y más importante aún cómo las ha implementado para llegar hasta donde está ahora.El trabajo está estructurado en cuatro grandes partes. La primera trata de analizar los factores que pueden tener un impacto en la actividad de la empresa, tanto a nivel externo como dentro de la compañía.En la segunda hemos estudiado la estrategia que ha seguido la empresa al lanzar su producto KH-7, qué decisiones ha tomado, qué factores ha resaltado, de qué cosas han prescindido...La tercera comprende el análisis del apartado de márketing. Cómo ha dado a conocer la empresa el producto y cómo ha conseguido que los clientes se decanten por su producto antes que el de la competencia.Y por último, la cuarta parte del trabajo consiste en las conclusiones, analiza los resultados que hemos obtenido al estudiar cada una de las partes anteriores.por último creemos que es importante explicar brevemente qué esperamos obtener nosotros de la realización de este proyecto. Creemos que lo más importante que podemos aprender de él es que no sólo triunfan las grandes marcas y las grandes multinacionales con presencia mundial. Si se encuentra una buena idea de negocio, que normalmente viene dada por un hueco en el mercado, y se desarrolla una política empresarial coherente con el nuevo producto, las posibilidades de tener éxito en el mercado son muy elevadas, y con este trabajo intentamos demostrarlo.

EPI Update, April 7, 2006

Weekly newsletter for Center For Acute Disease Epidemiology of Iowa Department of Public Health.

Motor Vehicle Accident Fatalities for the Week Ending, April 7, 2006

Record of the Fatalities for Motor Vehicle Accidents in Iowa per week.